Gene-Edited immune cells take on advanced cancers
NCT ID NCT05361174
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This early-phase trial is testing a personalized cell therapy called IOV-4001 for people with advanced melanoma or non-small-cell lung cancer. Doctors take a sample of the patient's tumor, grow and genetically modify the immune cells inside to remove a brake called PD-1, then infuse them back after a short course of chemotherapy. The goal is to see if this treatment is safe and can shrink tumors in 53 participants who have already tried other therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin
WITHDRAWNMilwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
Orlando Health Cancer Institute
RECRUITINGOrlando, Florida, 32610, United States
-
Sylvester Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33136, United States
-
The Angeles Clinic and Research Institute
RECRUITINGLos Angeles, California, 90025, United States
-
The University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45219, United States
-
University of Louisville
RECRUITINGLouisville, Kentucky, 40202, United States
-
Weill Medical College of Cornell University
RECRUITINGNew York, New York, 10022, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IOV-4001 (a personalized cell therapy made from a patient's own tumor-fighting immune cells, genetically modified to remove the PD-1 checkpoint)
What this could lead to
If successful, this could offer a new treatment option for people with advanced melanoma or lung cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 53 participants, so results may not apply to everyone. The treatment involves strong chemotherapy and carries risks like severe immune reactions or organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.